Get your free personalized podcast brief

We scan new podcasts and send you the top 5 insights daily.

Fordyce says Vera’s patient focus started before trials by choosing autoimmune disease and a mechanism aimed at inadequate standard of care. He points to steroid side effects—acute and chronic—as a real patient problem. He argues listening to patients reveals these harms and should shape target selection, not just marketing.

Related Insights

Beyond clinical endpoints, Palisade Bio emphasizes how quickly patients feel relief from IBD symptoms. They recognize that patients value immediate improvement and want to avoid trading disease discomfort for drug side effects. This patient-centric focus is a powerful differentiator in a crowded therapeutic area.

Marshall Fordyce says Vera’s 428-patient phase 3 trial had placebo volunteers losing 5–10% of kidney function yearly. Vera persuaded FDA to analyze early, showed Trutacna helped, and switched every placebo volunteer to the drug rather than waiting for more decline. That makes patient-centricity a trial-access and accountability mechanism.

For rare diseases without established clinical endpoints, biotech firms should co-design new endpoints with patients and their families. Presenting these patient-centric measures to the FDA builds a bond of trust and provides the agency with a clear, meaningful rationale for drug approval.

A common failure in biotech is viewing patients solely as data sources rather than as human partners in the development process. This perspective leads to unnecessarily complex protocols with high patient burden. The most successful firms build relationships with patient advocacy groups and design trials that respect the patient's experience.

The decision to found Skeletalis wasn't driven by a single lab breakthrough. Instead, it was the convergence of two distinct observations: clinically seeing patients' fear of existing drug side effects, and academically noticing a major gap at conferences between advanced animal model research and its translation into new human therapies.

Unlike typical autoimmune drugs that block or suppress the immune system, Nektar's ResPeg works by increasing anti-inflammatory cells. This mechanism allows for a marketing narrative centered on "restoring balance" rather than "inhibition," which can be more appealing and reassuring to patients wary of suppressing their immune system.

Haya's approach redefines the drug target. Instead of focusing on single proteins or pathways, they identify the "causal unit" of disease as the cellular behaviors that dictate how patients feel, function, and survive, and then work backwards to find a target.

A crucial piece of advice for biotech founders is to interact with patients as early as possible. This 'patient first' approach helps uncover unmet needs in their treatment journey, providing a more powerful and differentiated perspective than focusing solely on the scientific or commercial landscape.

Fordyce warns against cool molecule cartoons plus money and hope. He frames the problem as medical and the solution as scientific, requiring evidence across disease biology, molecule, PK, therapeutic window, and data from dish to animals to volunteers to patients. That disciplined translation reduces risk before expensive trials.

Acadia's R&D process starts by considering what will ultimately matter to patients, physicians, and payers. This "end in mind" approach ensures clinical trials are designed to demonstrate meaningful, commercially relevant benefits. It forces realism about a drug's potential impact early in development, avoiding wasted resources on therapies that won't be adopted.